This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Pfizer Sues J&J, Accuses it of Preventing Inflectra Uptake
by Zacks Equity Research
Pfizer (PFE) filed a lawsuit in a U.S. district court alleging that J&J is resorting to anticompetitive practices to prevent uptake of Inflectra.
Novartis Poised to Grow on Oncology Portfolio & Biosimilars
by Zacks Equity Research
Novartis expects the next growth phase to begin in 2018 driven by Cosentyx Entresto, Kisqali and Kymriah.
Biotech Stock Roundup: FDA Nod for First Cancer Biosimilar, HALO up on Deals, Raised Outlook
by Arpita Dutt
Data presentations, regulatory updates and licensing deals were among the key highlights this week with the focus being on the FDA approval of the first cancer biosimilar - Amgen's (AMGN) Mvasi.
Is Amgen (AMGN) a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if Amgen Inc. (AMGN) stock is a good choice for value-oriented investors right now from multiple angles.
Novartis Announces Positive Data on Urticaria Drug Xolair
by Zacks Equity Research
Novartis AG (NVS) announced new positive data on chronic spontaneous urticaria (CSU) drug Xolair from a phase IIIb study, OPTIMA.
Amgen/Allergan's Avastin Biosimilar Secures FDA Approval
by Zacks Equity Research
The FDA approves Amgen-Allergan's biosimilar version of Roche's Avastin for treating multiple types of cancers, to be marketed by the trade name of Mvasi.
Biosimilar 2017 Progress Report: Stocks in Focus
by Zacks Equity Research
The biosimilar space remains in the spotlight as a number of regulatory decisions are pending.
Novartis' BLA for Biosimilar of Rituxan Accepted by the FDA
by Zacks Equity Research
Novartis AG (NVS) announced that the FDA accepted its Biologics License Application for a proposed biosimilar version of Roche Holding AG's (RHHBY) Rituxan.
AbbVie's RA Candidate Meets Primary Endpoint in Phase III
by Zacks Equity Research
AbbVie's (ABBV) shares inch up with pipeline candidate upadacitinib meeting primary endpoints in a phase III study for treatment of rheumatoid arthritis.
Amgen/AstraZeneca Asthma Candidate Tezepelumab Shows Promise
by Zacks Equity Research
Amgen (AMGN) and AstraZeneca (AZN) announced promising data from a phase IIb study on tezepelumab, which reduced the rate of deterioration of asthma in patients with severe uncontrolled asthma.
AstraZeneca's COPD Candidate Duaklir Reports Positive Data
by Zacks Equity Research
AstraZeneca Plc (AZN) announced encouraging results from the phase III AMPLIFY study for Duaklir being developed for the treatment of chronic obstructive pulmonary disease (COPD).
Merck's (MRK) Keytruda Gets EU Approval for Bladder Cancer
by Zacks Equity Research
Merck's (MRK) Keytruda received approval in the EU for the first and second line treatment of certain patients with advanced bladder cancer.
Ligand (LGND) Diabetes Candidate Positive in Phase II Study
by Zacks Equity Research
Ligand's (LGND) diabetes candidate, LGD-6972, demonstrated a change of statistical significance in blood glucose level (HbA1c) from baseline over a treatment period of 12 weeks.
Biotech Stock Roundup: Cellectis Down on Clinical Hold, Insmed Soars on Positive Data
by Arpita Dutt
Key highlights include pipeline updates from companies like Cellectis (CLLS) and Insmed. Insmed's shares skyrocketed on positive data from a late-stage study.
Amgen Gets EU Nod to Expand Hyperparathyroidism Drug Label
by Zacks Equity Research
The European Commission approves Amgen's (AMGN) marketing application for Mimpara's pediatric formulation to heal secondary hyperparathyroidism (HPT).
Immunogen Inks Deal With Jazz Pharma to Develop ADC Molecule
by Zacks Equity Research
ImmunoGen (IMGN) and Jazz Pharma announced a strategic collaboration to develop and commercialize antibody-drug conjugate products.
Amgen Presents New Repatha Analysis from FOURIER Study
by Zacks Equity Research
Amgen's (AMGN) new analysis from FOURIER study on Repatha showed that there was a strong progressive relationship between lower levels of bad cholesterol and a lower risk of cardiovascular events rates.
Biogen's Humira Biosimilar Imraldi Gets Approval in EU
by Zacks Equity Research
Biogen Inc.'s (BIIB) biosimilar version of AbbVie's top-selling blockbuster drug, Humira has been approved by the European Commission.
Amgen (AMGN) Down 6.4% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Can Sanofi (SNY) Sustain the Solid 1H Momentum in 2H17?
by Zacks Equity Research
Sanofi, Inc. (SNY) performed quite well in the first half of 2017 and looks well poised to carry on the momentum in the second half.
Biotech Stock Roundup: EU Label Expansion for Alexion, BIIB Facing Drug Price Probe
by Arpita Dutt
Key highlights include regulatory approvals for companies like Alexion (ALXN) and Ironwood while Biogen is one of the companies facing an investigation into the pricing of multiple sclerosis drugs.
Can Ligand's Captisol Deals Boost Growth in the Long Run?
by Zacks Equity Research
Ligand's (LGND) Captisol formulation technology platform allows it to partner with several leading drug companies, earning milestones and royalty payments from the same.
Are Amgen's New Drugs Doing Well Enough to Drive Sales?
by Zacks Equity Research
Higher volumes of Amgen, Inc.'s (AMGN) new products may not be enough to offset the lost sales due to the decline in mature brands.
Ligand (LGND) Q2 Earnings & Revenues Top, 2017 View Raised
by Zacks Equity Research
Ligand's (LGND) earnings and revenues beat estimates. Total revenue also rises year over on the back of higher royalty benefits. The company ups its outlook for 2017.
Radius (RDUS) Q2 Loss Wider than Expected on Higher Expenses
by Zacks Equity Research
Radius Health, Inc. (RDUS) posted a wider-than-expected loss in the second quarter due to an increase in general and administrative expenses.